Chengdu Kanghua Biological Products Co., Ltd. (300841.SZ)
CNY 57.39
(-0.92%)
CNY 57.39
(-0.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 576.61 Million CNY | -12.62% |
| 2022 | 685.5 Million CNY | -25.14% |
| 2021 | 915.75 Million CNY | 88.79% |
| 2020 | 485.05 Million CNY | 117.12% |
| 2019 | 223.4 Million CNY | 17.81% |
| 2018 | 189.62 Million CNY | 108.6% |
| 2017 | 90.9 Million CNY | 1249.95% |
| 2016 | 6.73 Million CNY | -50.1% |
| 2015 | 13.49 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | 111.23 Million CNY | -37.83% |
| 2024 Q1 | 168.84 Million CNY | -18.34% |
| 2024 Q2 | 178.91 Million CNY | 5.96% |
| 2023 Q4 | 206.75 Million CNY | 58.55% |
| 2023 FY | 598.99 Million CNY | -12.62% |
| 2023 Q1 | 117.03 Million CNY | -13.02% |
| 2023 Q2 | 161.08 Million CNY | 37.63% |
| 2023 Q3 | 130.4 Million CNY | -19.05% |
| 2022 Q4 | 134.56 Million CNY | -28.91% |
| 2022 FY | 685.5 Million CNY | -25.14% |
| 2022 Q2 | 205.5 Million CNY | 31.62% |
| 2022 Q1 | 156.13 Million CNY | -41.05% |
| 2022 Q3 | 189.29 Million CNY | -7.89% |
| 2021 Q1 | 118.96 Million CNY | 51.99% |
| 2021 Q4 | 264.84 Million CNY | -24.8% |
| 2021 FY | 915.75 Million CNY | 88.79% |
| 2021 Q3 | 352.2 Million CNY | 95.96% |
| 2021 Q2 | 179.73 Million CNY | 51.08% |
| 2020 Q1 | 77.23 Million CNY | -33.6% |
| 2020 FY | 485.05 Million CNY | 117.12% |
| 2020 Q2 | 139.01 Million CNY | 79.98% |
| 2020 Q3 | 190.52 Million CNY | 37.05% |
| 2020 Q4 | 78.27 Million CNY | -58.92% |
| 2019 Q3 | 5.01 Million CNY | -91.67% |
| 2019 FY | 223.4 Million CNY | 17.81% |
| 2019 Q4 | 116.32 Million CNY | 2217.56% |
| 2019 Q2 | 60.23 Million CNY | 44.03% |
| 2019 Q1 | 41.82 Million CNY | 111.0% |
| 2018 Q4 | 19.82 Million CNY | 0.0% |
| 2018 FY | 189.62 Million CNY | 108.6% |
| 2017 FY | 90.9 Million CNY | 1249.95% |
| 2016 FY | 6.73 Million CNY | -50.1% |
| 2015 FY | 13.49 Million CNY | 0.0% |